Follow Up to the January 3, 2008 Communication About an Ongoing Safety Review Erythropoiesis-Stimulating Agents (ESAs) Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp) This information reflects FDA’s current analysis of available data concerning these drugs. FDA intends to update this document when additional information or analyses become available. ROCKVILLE, Md., July 30, 2008--On April 22, 2008, FDA notified the manufacturer of Epogen/Procrit and Aranesp of its decision to require additional safety-related changes to the labeling for these products. Amgen submitted labeling supplements for Epogen/Procrit and Aranesp on May 22, 2008, following the March 13, 2008 Oncologic Advisory Committee’s recommendations to make additional safety-related changes to the labeling for these products. gambling law nc video on samsung blackjack black casino free game jack play blackjack phone linux online casinos that use paypal